G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Intrinsic Value

The intrinsic value of one GLS stock under the Base Case scenario is 715.71 INR. Compared to the current market price of 1 045.65 INR, Glenmark Life Sciences Ltd is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Glenmark Life Sciences Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GLS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GLS?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Glenmark Life Sciences Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Glenmark Life Sciences Ltd

Provide an overview of the primary business activities
of Glenmark Life Sciences Ltd.

What unique competitive advantages
does Glenmark Life Sciences Ltd hold over its rivals?

What risks and challenges
does Glenmark Life Sciences Ltd face in the near future?

Has there been any significant insider trading activity
in Glenmark Life Sciences Ltd recently?

Summarize the latest earnings call
of Glenmark Life Sciences Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Glenmark Life Sciences Ltd.

Provide P/S
for Glenmark Life Sciences Ltd.

Provide P/E
for Glenmark Life Sciences Ltd.

Provide P/OCF
for Glenmark Life Sciences Ltd.

Provide P/FCFE
for Glenmark Life Sciences Ltd.

Provide P/B
for Glenmark Life Sciences Ltd.

Provide EV/S
for Glenmark Life Sciences Ltd.

Provide EV/GP
for Glenmark Life Sciences Ltd.

Provide EV/EBITDA
for Glenmark Life Sciences Ltd.

Provide EV/EBIT
for Glenmark Life Sciences Ltd.

Provide EV/OCF
for Glenmark Life Sciences Ltd.

Provide EV/FCFF
for Glenmark Life Sciences Ltd.

Provide EV/IC
for Glenmark Life Sciences Ltd.

Show me price targets
for Glenmark Life Sciences Ltd made by professional analysts.

What are the Revenue projections
for Glenmark Life Sciences Ltd?

How accurate were the past Revenue estimates
for Glenmark Life Sciences Ltd?

What are the Net Income projections
for Glenmark Life Sciences Ltd?

How accurate were the past Net Income estimates
for Glenmark Life Sciences Ltd?

What are the EPS projections
for Glenmark Life Sciences Ltd?

How accurate were the past EPS estimates
for Glenmark Life Sciences Ltd?

What are the EBIT projections
for Glenmark Life Sciences Ltd?

How accurate were the past EBIT estimates
for Glenmark Life Sciences Ltd?

Compare the revenue forecasts
for Glenmark Life Sciences Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Glenmark Life Sciences Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Glenmark Life Sciences Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Glenmark Life Sciences Ltd compared to its peers.

Compare the P/E ratios
of Glenmark Life Sciences Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Glenmark Life Sciences Ltd with its peers.

Analyze the financial leverage
of Glenmark Life Sciences Ltd compared to its main competitors.

Show all profitability ratios
for Glenmark Life Sciences Ltd.

Provide ROE
for Glenmark Life Sciences Ltd.

Provide ROA
for Glenmark Life Sciences Ltd.

Provide ROIC
for Glenmark Life Sciences Ltd.

Provide ROCE
for Glenmark Life Sciences Ltd.

Provide Gross Margin
for Glenmark Life Sciences Ltd.

Provide Operating Margin
for Glenmark Life Sciences Ltd.

Provide Net Margin
for Glenmark Life Sciences Ltd.

Provide FCF Margin
for Glenmark Life Sciences Ltd.

Show all solvency ratios
for Glenmark Life Sciences Ltd.

Provide D/E Ratio
for Glenmark Life Sciences Ltd.

Provide D/A Ratio
for Glenmark Life Sciences Ltd.

Provide Interest Coverage Ratio
for Glenmark Life Sciences Ltd.

Provide Altman Z-Score Ratio
for Glenmark Life Sciences Ltd.

Provide Quick Ratio
for Glenmark Life Sciences Ltd.

Provide Current Ratio
for Glenmark Life Sciences Ltd.

Provide Cash Ratio
for Glenmark Life Sciences Ltd.

What is the historical Revenue growth
over the last 5 years for Glenmark Life Sciences Ltd?

What is the historical Net Income growth
over the last 5 years for Glenmark Life Sciences Ltd?

What is the current Free Cash Flow
of Glenmark Life Sciences Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Glenmark Life Sciences Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Glenmark Life Sciences Ltd

Current Assets 21B
Cash & Short-Term Investments 5.3B
Receivables 7.8B
Other Current Assets 7.9B
Non-Current Assets 9.9B
Long-Term Investments 111.2m
PP&E 9.5B
Intangibles 172.7m
Other Non-Current Assets 152.9m
Current Liabilities 4.6B
Accounts Payable 4B
Accrued Liabilities 138.5m
Other Current Liabilities 517.2m
Non-Current Liabilities 826.5m
Long-Term Debt 133.8m
Other Non-Current Liabilities 692.7m
Efficiency

Earnings Waterfall
Glenmark Life Sciences Ltd

Revenue
22B INR
Cost of Revenue
-9.9B INR
Gross Profit
12.1B INR
Operating Expenses
-6.6B INR
Operating Income
5.5B INR
Other Expenses
-1.3B INR
Net Income
4.2B INR

Free Cash Flow Analysis
Glenmark Life Sciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GLS Profitability Score
Profitability Due Diligence

Glenmark Life Sciences Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Year Average ROIC
Positive 3-Year Average ROE
Positive Free Cash Flow
60/100
Profitability
Score

Glenmark Life Sciences Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

GLS Solvency Score
Solvency Due Diligence

Glenmark Life Sciences Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Glenmark Life Sciences Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLS Price Targets Summary
Glenmark Life Sciences Ltd

Wall Street analysts forecast GLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLS is 1 102.11 INR with a low forecast of 797.9 INR and a high forecast of 1 359.75 INR.

Lowest
Price Target
797.9 INR
24% Downside
Average
Price Target
1 102.11 INR
5% Upside
Highest
Price Target
1 359.75 INR
30% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GLS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GLS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GLS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Glenmark Life Sciences Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

128.1B INR

Dividend Yield

0%

Description

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

Contact

MAHARASHTRA
Solapur
Glenmark House, B. D. Sawant Marg, Andheri (East)
+912240189999
www.glenmarklifesciences.com

IPO

2021-08-06

Employees

1 537

Officers

CEO, MD & Director
Dr. Yasir Yusufali Rawjee Ph.D.
Senior VP & CFO
Mr. Tushar P. Mistry
Group VP, Head of Technical Operations & Whole Time Director
Mr. Vinod Naik
Company Secretary & Compliance Officer
Mr. Rudalf Corriea
General Manager of Corporate Communications
Soumi Rao
Senior VP & Head of Human Resources
Mr. Sumantra Mitra
Show More
Senior VP & Head of Regulatory Affairs
Mr. Mathew George
VP & Head of Corporate Quality
Mr. Navin Kumar Agrawal
Show Less

See Also

Discover More
What is the Intrinsic Value of one GLS stock?

The intrinsic value of one GLS stock under the Base Case scenario is 715.71 INR.

Is GLS stock undervalued or overvalued?

Compared to the current market price of 1 045.65 INR, Glenmark Life Sciences Ltd is Overvalued by 32%.

Back to Top